리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 367 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 뇌졸중 치료제 시장은 2030년까지 57억 달러에 도달
2024년에 40억 달러로 추정되는 세계의 뇌졸중 치료제 시장은 2024-2030년의 분석 기간에 CAGR 6.0%로 성장하며, 2030년에는 57억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 허혈성 뇌졸중은 CAGR 5.1%를 기록하며, 분석 기간 종료시에는 38억 달러에 달할 것으로 예측됩니다. 출혈성 뇌졸중 부문의 성장률은 분석 기간 중 CAGR 8.1%로 추정됩니다.
미국 시장은 11억 달러로 추정, 중국은 CAGR 9.3%로 성장할 것으로 예측
미국의 뇌졸중 치료제 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 9.3%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.0%와 5.8%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.
세계의 뇌졸중 치료제 시장 - 주요 동향과 촉진요인 정리
뇌졸중 치료제는 급성기 중재, 2차 예방 전략, 뇌졸중 후 재활 보조 등 진화하는 범위를 포괄하고 있습니다. 혈전 용해제에서 신경 보호제, 이식형 신경 자극기에서 가상현실 재활 플랫폼에 이르기까지 이 분야는 계속 확장되고 있습니다. 현재 시장 동향은 초급성기부터 만성기 회복까지 뇌졸중의 전 과정에 대응하는 생물제제, 첨단 기기 치료, 통합적 치료 제공 시스템의 혁신으로 형성되고 있습니다.
웨어러블 센서와 뇌졸중을 감지하는 스마트워치는 뇌졸중이 발생하기 전에 심방세동과 일과성 뇌허혈 발작을 감지합니다. 원격의료 플랫폼은 또한 원격지나 자원이 부족한 지역에서 신속한 신경과 진료를 보장하고, 급성기 치료를 위한 문에서 바늘까지 걸리는 시간을 단축시킵니다.
생물제제와 혈전 제거 장치가 프론티어를 형성하는가?
조직 플라스미노겐 활성화 인자(tPA)와 같은 혈전 용해제는 허혈성 뇌졸중 치료의 최전선 치료제로서 계속 사용되고 있습니다. 그러나 치료 기간을 연장하고 출혈 위험을 낮추는 새로운 유형의 약물이 개발되고 있습니다. 한편, 기계적 혈전 제거 장치인 스텐트 리트리버와 흡입 카테터는 급성 허혈성 뇌졸중 치료를 재정의하고 있으며, 일부 환자의 경우 증상 발현 후 24시간까지 치료할 수 있게 되었습니다.
신경 보호와 관련하여, 글루타메이트의 흥분 독성 및 산화 스트레스 경로를 표적으로 하는 단일 클론 항체가 경색 크기 감소에 유망 것으로 나타났습니다. 줄기세포와 엑소좀을 이용한 세포 기반 치료법은 신경세포의 재생을 촉진하는 것을 목표로 하고 있습니다. 이러한 접근법은 특히 아급성기나 만성기 회복기에 초점을 맞춘 임상시험에서 주목받고 있습니다.
뇌졸중 후 재활은 디지털 르네상스를 맞이하는가?
재활은 급격한 디지털화를 맞이하고 있습니다. 상지 및 하지 치료용 로봇 외골격은 환자가 더 높은 반복 횟수와 정확한 측정 결과로 운동 기능을 회복할 수 있도록 돕습니다. 가상현실과 게이미피케이션된 치료 시스템은 환자를 몰입형 환경으로 끌어들여 순응도와 신경 가소성을 자극하는 데 도움을 줍니다.
인지 기능 회복을 위해 사용자의 성과에 따라 난이도를 조절하는 AI 기반 두뇌 트레이닝 앱도 도움이 되고 있습니다. 음성 언어 치료는 음성 인식 엔진이 탑재된 원격 진료 플랫폼에 의해 보완되어 원격으로 보충 세션을 가능하게 합니다. 이러한 디지털 방식은 회복을 앞당길 뿐만 아니라, 제한된 비율로 운영되는 재활센터의 부담을 덜어주는데도 도움이 될 수 있습니다.
뇌졸중 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.
시장 확대에는 뚜렷한 분야별 촉진요인이 있습니다. 첫째, 고령화 및 당뇨-고혈압 등 위험요인 증가로 인한 전 세계 뇌졸중 발병률 증가로 급성기, 예방기, 회복기에 걸쳐 수요가 확대되고 있습니다. 신경중재치료기기와 혈전 용해제의 개발로 치료 가능한 환자층이 확대되어 기기 보급률을 직접적으로 끌어올리고 있습니다. 디지털 재활 플랫폼과 원격 뇌졸중 기술은 인프라 개선과 원격 및 재택 치료에 대한 보험사 환급으로 인해 보급이 확대되고 있습니다.
또한 가치 기반 치료를 중시하는 정책은 EMS, 급성기 치료, 재활, 2차 예방에 걸친 통합 뇌졸중 프로그램에 대한 투자를 촉진하여 번들 솔루션에 대한 시장 견인력을 창출하고 있습니다. 마지막으로 벤처캐피털과 민관 파트너십을 통한 자금 조달로 생물제제, 신경보철, 정밀 재활 툴의 파이프라인 개발이 가속화되고 있습니다.
부문
유형(허혈성 뇌졸중, 출혈성 뇌졸중), 치료제(조직 플라스미노겐 활성화약, 항응고제, 항혈소판제, 기타 치료제), 최종사용자(병원, 진료소, 기타 최종사용자)
조사 대상 기업의 예
Anthos Therapeutics(now Novartis)
AstraZeneca
Bayer AG
Biogen(Genentech/Roche)
Boehringer Ingelheim
Bristol-Myers Squibb
Cadrenal Therapeutics
Cerenova Bioscience
Daiichi Sankyo
Eisai Co., Ltd.
H. Lundbeck A/S
Johnson & Johnson
Lupin Ltd.
Merck & Co.
Novartis AG
Pfizer Inc.
Prestige Consumer Healthcare
Roche(Genentech subsidiary)
Sanofi S.A.
Zealand Pharma A/S
AI 통합
당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Stroke Therapeutics Market to Reach US$5.7 Billion by 2030
The global market for Stroke Therapeutics estimated at US$4.0 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Ischemic Stroke, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Hemorrhagic Stroke segment is estimated at 8.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.3% CAGR
The Stroke Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.
Global Stroke Therapeutics Market - Key Trends & Drivers Summarized
Stroke therapeutics encompass an evolving range of acute interventions, secondary prevention strategies, and post-stroke rehabilitation aids. From clot-busting thrombolytics to neuroprotective agents, and from implantable neurostimulators to virtual-reality rehab platforms, this field continues to expand. The current market trajectory is shaped by innovation in biologics, advanced device therapy, and integrated care delivery systems that address the full stroke continuum-from hyper-acute to chronic recovery.
Emerging tools combine real-time patient monitoring with AI algorithms: wearable sensors and stroke-detecting smartwatches now flag atrial fibrillation episodes or transient ischemic attacks before a full stroke occurs. Telehealth platforms further ensure rapid neurology consultation in remote or under-resourced regions, reducing door-to-needle time for acute therapy.
Are Biologics and Thrombectomy Devices Shaping the Frontier?
Thrombolytic drugs, such as tissue plasminogen activator (tPA), remain the frontline in ischemic stroke. Yet new variants with extended therapeutic windows and lower hemorrhagic risk are under development. Meanwhile, mechanical thrombectomy devices-stent retrievers and aspiration catheters-have redefined acute ischemic stroke care, enabling treatment up to 24 hours after symptom onset in select patients.
On the neuroprotection front, monoclonal antibodies targeting glutamate excitotoxicity and oxidative stress pathways show promise in mitigating infarct size. Cell-based therapies using stem cells or exosomes aim to promote neuronal regeneration. These approaches gain traction, particularly in trials focusing on subacute and chronic recovery phases.
Is Post-Stroke Rehabilitation Entering a Digital Renaissance?
Rehabilitation is undergoing dramatic digitization. Robotic exoskeletons for upper and lower limb therapy help patients regain motor function with higher repetitions and precisely measured outcomes. Virtual-reality and gamified therapy systems engage patients in immersive environments-encouraging adherence and neuroplasticity stimulation.
Cognitive recovery is also benefiting from AI-driven brain-training apps that adapt difficulty based on user performance. Speech-language therapy is being supplemented by tele-practice platforms equipped with speech recognition engines, enabling remote remedial sessions. These digital modalities not only accelerate recovery but also help reduce pressure on ratio-limited rehab centers.
The Growth in the Stroke Therapeutics Market Is Driven by Several Factors…
The market’s expansion is fueled by clear, sector-specific drivers. One is the global increase in stroke incidence-stemming from aging populations and rising risk factors like diabetes and hypertension-escalating demand across acute, prevention, and recovery phases. Innovations in neurointerventional devices and extended-window thrombolytics have widened the treatable patient population, directly boosting device adoption rates. Digital rehab platforms and telestroke technologies are seeing increased uptake due to improved infrastructure and insurer reimbursements for remote and home-based care.
Furthermore, policy emphasis on value-based care has encouraged investment in integrated stroke programs-spanning EMS, acute therapy, rehab, and secondary prevention-creating market pull for bundled solutions. Finally, venture capital and public-private partnership funding has accelerated pipeline development for biologics, neuroprosthetics, and precision rehabilitation tools.
SCOPE OF STUDY:
The report analyzes the Stroke Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Ischemic Stroke, Hemorrhagic Stroke); Treatment (Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment, Other Treatments); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 34 Featured) -
Anthos Therapeutics (now Novartis)
AstraZeneca
Bayer AG
Biogen (Genentech/Roche)
Boehringer Ingelheim
Bristol-Myers Squibb
Cadrenal Therapeutics
Cerenova Bioscience
Daiichi Sankyo
Eisai Co., Ltd.
H. Lundbeck A/S
Johnson & Johnson
Lupin Ltd.
Merck & Co.
Novartis AG
Pfizer Inc.
Prestige Consumer Healthcare
Roche (Genentech subsidiary)
Sanofi S.A.
Zealand Pharma A/S
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Stroke Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Ischemic and Hemorrhagic Stroke Globally Throws the Spotlight on Stroke Treatment Innovations
Accelerated Emergency Response Infrastructure Drives Demand for Fast-Acting Thrombolytics and Anticoagulants
Expansion of Stroke Awareness and Screening Programs Spurs Early Diagnosis and Therapeutic Intervention
Technological Advances in Clot Retrieval Devices Strengthen Business Case for Endovascular Stroke Therapies
Increasing Adoption of AI-Based Imaging for Stroke Diagnosis Enhances Precision and Time-to-Treatment
Pipeline Expansion of Neuroprotective Agents and Regenerative Therapies Propels Investment in Stroke R&D
Growing Aging Population and Associated Stroke Risk Expands Demand for Long-Term Care and Therapeutics
Favorable Reimbursement Policies in Developed Economies Drive Adoption of High-Cost Stroke Treatments
Integration of Rehabilitation and Secondary Prevention Strategies Expands Role of Combination Stroke Therapeutics
Rise of Telemedicine in Emergency Stroke Management Supports Wider Accessibility to Timely Therapies
Partnerships Between Pharma and Neuroscience Startups Fuel Innovation in Targeted Stroke Drug Development
Regulatory Fast-Track Approvals for Life-Saving Stroke Drugs Accelerate Market Entry for New Therapies
Post-Stroke Disability Reduction Goals Generate Opportunities for Adjunct Therapies and Cognitive Support Treatments
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Stroke Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Stroke Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Stroke Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Stroke Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Ischemic Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Ischemic Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Ischemic Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Hemorrhagic Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Hemorrhagic Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Hemorrhagic Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Tissue Plasminogen Activators Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Tissue Plasminogen Activators Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Tissue Plasminogen Activators Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Anticoagulants Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Anticoagulants Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Anticoagulants Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Antiplatelets Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Antiplatelets Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Antiplatelets Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: USA 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: USA 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: USA 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: Canada 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: Canada 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: Canada 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
JAPAN
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: Japan 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Japan 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Japan 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CHINA
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: China 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: China 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: China 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
EUROPE
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Stroke Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: Europe 16-Year Perspective for Stroke Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: Europe 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: Europe 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: Europe 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
FRANCE
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 80: France Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: France 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: France 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: France 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
GERMANY
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 89: Germany Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Germany 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Germany 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Germany 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Italy 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Italy 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Italy 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED KINGDOM
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 107: UK Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: UK 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: UK 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: UK 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SPAIN
TABLE 116: Spain Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Spain 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: Spain 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: Spain 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
RUSSIA
TABLE 125: Russia Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: Russia 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: Russia 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Russia 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Rest of Europe 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Stroke Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Stroke Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Asia-Pacific 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AUSTRALIA
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 155: Australia Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Australia 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Australia 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Australia 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
INDIA
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 164: India Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: India Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: India 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: India 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: India 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 173: South Korea Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: South Korea 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: South Korea 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
LATIN AMERICA
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 191: Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Stroke Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Latin America 16-Year Perspective for Stroke Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: Latin America 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 203: Argentina Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Argentina 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Argentina 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
BRAZIL
TABLE 212: Brazil Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Brazil 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 217: Brazil 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MEXICO
TABLE 221: Mexico Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 223: Mexico 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 226: Mexico 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 232: Rest of Latin America 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 235: Rest of Latin America 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MIDDLE EAST
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 239: Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Stroke Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 241: Middle East 16-Year Perspective for Stroke Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 244: Middle East 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
IRAN
TABLE 251: Iran Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 253: Iran 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 256: Iran 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 259: Iran 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ISRAEL
TABLE 260: Israel Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 262: Israel 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 265: Israel 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 268: Israel 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 271: Saudi Arabia 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 274: Saudi Arabia 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 278: UAE Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 280: UAE 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 283: UAE 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 286: UAE 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 289: Rest of Middle East 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 292: Rest of Middle East 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AFRICA
Stroke Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 296: Africa Recent Past, Current & Future Analysis for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Stroke Therapeutics by Type - Ischemic Stroke and Hemorrhagic Stroke Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 298: Africa 16-Year Perspective for Stroke Therapeutics by Type - Percentage Breakdown of Value Sales for Ischemic Stroke and Hemorrhagic Stroke for the Years 2014, 2025 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Stroke Therapeutics by Treatment - Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 301: Africa 16-Year Perspective for Stroke Therapeutics by Treatment - Percentage Breakdown of Value Sales for Tissue Plasminogen Activators Treatment, Anticoagulants Treatment, Antiplatelets Treatment and Other Treatments for the Years 2014, 2025 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Stroke Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 304: Africa 16-Year Perspective for Stroke Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030